Navigation Links
Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
Date:6/18/2009

ward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials, including possible delays in initiating or completing the trials and safety and efficacy results; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
2. Novavax Reports First Quarter 2009 Financial Results
3. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
4. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
5. Novavax Announces Early Retirement of $17 Million of Convertible Debt
6. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
7. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
8. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
9. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
10. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
11. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015 Research and Markets ( ... "Middle East & Africa Biomedical Sensors Market - Growth, ... The Middle East ... $0.84 billion by 2018 at a CAGR of 3.26% ... will bring Biomedical sensors that are adaptable to the ...
(Date:8/31/2015)... and SHANGHAI , Aug. ... biopharmaceutical company developing next-generation antibiotics, today announced positive ... study for its lead drug candidate MRX-I. MRX-I ... drug-resistant bacteria such as MRSA and VRE, while ... tolerated therapeutic option than currently available oxazolidinone agents. ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Food Processing Suppliers Association's ... processors, equipment manufacturers and leaders in the field of academia. , METTLER ... for manufacturers of bakery and snacks; beverages; dairy; meat, poultry and seafood; and ...
(Date:8/28/2015)... PUNE, India , August 28, 2015 ... Market, by Product (Media, Sera, Cryogenic Storage Systems, Thawing ... Application (Therapeutic, Regenerative Medicine, Clinical Trials), End User - ... Biopreservation Market is expected to reach USD 3,731.03 Million ... at a CAGR of 11.65% between 2015 and 2020. ...
Breaking Biology Technology:Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2METTLER TOLEDO Hosts Food Safety Educational Center at 2015 PROCESS EXPO 2Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5
... PETACH TIKVA, Israel, August 16 Healthcare,Technologies Ltd. (NASDAQ: ... an,extraordinary general meeting of its shareholders to be held ... of Yigal Arnon & Co., 1 Azrieli,Center, Round Tower, ... shareholders will be asked to approve the previously,announced Asset ...
... Support for Vermed Sale, SAN DIEGO, Aug. 16 ... and leader of,impedance cardiography (ICG) technology, today announced that ... well with over 50%,of the necessary shareholder votes (approximately ... Vermed sale. The ratio of votes,received is running in ...
... affiliate of,Phlo Corporation (OTC: PHLC) (the "Company") announced ... now been expanded to the San,Francisco and Napa/Sonoma ... and stretching to the Oregon border. New ... Grocery in Palo Alto, Zanotto,s Grocery in Silicon ...
Cached Biology Technology:Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction 2Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction 3CardioDynamics Provides 2007 Shareholder Meeting Update 2CardioDynamics Provides 2007 Shareholder Meeting Update 3Phlo Affiliate Reports Expanded Coverage to Oregon Border 2
(Date:8/5/2015)... VIEW, Calif. , Aug. 5, 2015 ... exhibits continuous growth in applications, penetration into newer sectors, ... after year. The global biosensors space has seen the ... exited the market so far. (Photo - ... Frost & Sullivan, Analysis of the Global Biosensors ...
(Date:8/4/2015)...  AMRI (NASDAQ: AMRI ) today reported financial and operating ... Highlights: , Second quarter contract revenue of $ ... , Adjusted contract margins of 26 % ... $0.05 decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial quarter, ...
(Date:7/31/2015)... SHENZHEN , Kina, 31. juli 2015 ... ) bliver afholdt af BGI fra den 22. - 25. ... Konferencen fejrer sin 10-års fødselsdag i år. ... verdens mest indflydelsesrige årlige møder på ,omik,-feltet, og er ... forsamlinger. ICG-10 fokuserer på nylige gennembrud ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... By coupling a kicked-up version of microscopy with miniscule particles ... so deep into living tissue that they can see molecules ... the researchers believe that their new approach can have a ... a tumor as it is removed from the body to ...
... Any way you slice it, the planarian,s contributions to biological ... a flatworm normally living in freshwater, is well known for ... into 200 pieces can generate 200 new individuals. New research ... master of regeneration, but can help scientists understand the basis ...
... mother of two to promote company,s highly secure, do ... yourself, smartTOUCH(R) finger activated products, JERICHO, ... today announced that it has hired Debbe Dunning as,the ... it,embarks upon an advertising campaign directed at the Home ...
Cached Biology News:New technique sees into tissue at greater depth, resolution 2New technique sees into tissue at greater depth, resolution 3'Home Improvement' Star Debbe Dunning is New smartTOUCH Spokesperson 2'Home Improvement' Star Debbe Dunning is New smartTOUCH Spokesperson 3
Mouse Anti-Human Kallikrein 2 (Hk2)...
... to Asb-2 (Ankyrin repeat and SOCS box-containing ... synthetic peptides containing amino acids 75-93 and ... lysate (Imgenex Catalog No. 40149) can be ... cross react with mouse and rat Asb-2, ...
Recognizes TWIK-2. Does not cross react with any other known proteins....
... Glycine Transporter 2, Neuronal (GLYT2). The ... from the central nervous system. The staining ... pattern described using in situ hybridization with ... has been described for glycinergic neurons. Preabsorption ...
Biology Products: